All In Biotech

Drug Trial Radar · NCT04228783

A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN®-Filo in Adult Participants

Last checked: Nov 19, 2026Latest source record: May 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 974 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

974

Actual

Start

Feb 18, 2020

Primary completion

Apr 25, 2022

Study completion Apr 25, 2022

Sponsor

Lead sponsor
Janssen Vaccines & Prevention B.V.Johnson & Johnson (Janssen) (JNJ)
Sponsor type
Industry
First posted
Jan 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactured lots of Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) including the ebola virus mayinga glycoprotein as Dose 2, administered at a 56-day interval, induce an equivalent humoral immune response.

Conditions

  • Ebola

Interventions

  • Ad26.ZEBOVBiological

    Participants will receive IM injection (0.5 mL) of Ad26.ZEBOV as Dose 1 (5\*10\^10 vp, Lot A, B, and C) on Day 1 (Groups 1, 2, 3 and 5) and an Ad26.ZEBOV booster dose on Day 177 (Group 5).

  • MVA-BN-FiloBiological

    Participants will receive IM injection (0.5 mL) of MVA-BN-Filo as Dose 2 (1\*10\^8 Inf U, Lot 1, 2, 3 and 5) on Day 57.

  • PlaceboBiological

    Participants will receive IM injection (0.5 mL) of placebo (0.9 % saline) as Dose 1 on Day 1, followed by placebo as Dose 2 on Day 57 (Groups 4 and 6) and a booster of matching placebo on Day 177 (Group 6).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against the Ebola Virus Glycoprotein (EBOV GP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) at 21 Days Post Vaccination 2Time frame: 21 Days Post Vaccination 2 (Day 78)

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Coastal Clinical Research, Inc

    Mobile, Alabama

  • Clinical Research Consortium, an AMR company

    Tempe, Arizona

  • Central Kentucky Research Associates, Inc.

    Lexington, Kentucky

  • The Center For Pharmaceutical Research

    Kansas City, Missouri

  • Clinical Research Consortium, an AMR company

    Las Vegas, Nevada

  • AMR New Orleans, Formerly New Orleans Center for Clinical Research - New Orleans, an AMR company

    Knoxville, Tennessee

  • Alliance for Multispeciality Research

    Norfolk, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.